A Phase 4 interventional study of Brexpiprazole in Major Depressive Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-02-02.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 14th largest by enrollment, is the only one that started in 2021, is one of 3 in phase 4, and was the 22nd registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Nova Scotia Health Authority · Sites in Canada
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 17 · Phase 4 3
First in 2009; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 122 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 189 across the 24 interventional studies. Of the 21 that completed or were terminated, 19 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 24 have an industry lead sponsor. The 6 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 42 finished, 29 (69%) have results posted.
Among the 45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd., this one is the 28th largest by enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2021, is one of 4 in phase 4, and was the 39th registered.
Otsuka Holdings Co., Ltd.’s Depressive Disorder, Major studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 45 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The clinical trial will investigate the effect of brexpiprazole on the concept of life engagement in participants with Major Depressive Disorder (MDD) with a current depressive episode.
This is a phase 4, multicenter, open-label, flexible dose trial designed to assess the effects of brexpiprazole (flexible dose; 0.5 to 2 milligrams [mg], once daily [QD]) as adjunctive therapy to antidepressant therapy (ADT) on life engagement in participants with MDD. This trial is being conducted in line with the Canadian Product Monograph.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with a concurrent diagnosis of the following will be excluded:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received brexpiprazole as a flexible dose; 0.5 mg to 2 mg, orally (PO), QD, and continued on the stable dose of ADT up to 8 weeks.
Drug: Brexpiprazole
Oral brexpiprazole tablets as adjunctive therapy to ADT
Also known as: OPC-34712
Change From Baseline in IDS-SR-10 Engagement
The IDS-SR-10 engagement consist of selected 10 item scores, including the following 10 items (clinician-selected): item 8 - Response of your mood to good or desired events, item 15 - Concentration/decision making, item 16 - View of myself, item 17 - View of my future, item 19 - General interest, item 20 - Energy level, item 21 - Capacity for pleasure or enjoyment (excluding sex), item 22 - Interest in sex (interest rated, not activity), item 23 - Feeling slowed down, and item 29- Interpersonal sensitivity. All the 10 items are rated on a 0 (best) to 3 (worst) scale. IDS-SR-10 engagement total score ranges from 0 (best) to 30 (worst). A negative change from baseline indicated improvement. Least square (LS) mean was calculated using a mixed model repeated measure (MMRM) analysis.
Time frame: Baseline to Week 8
Change From Baseline in IDS-SR Total Score
The IDS-SR is a 30-item self-report measure that was used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of major depressive disorder (MDD). Each item on the IDS-SR scale was rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. IDS-SR total score is the sum of ratings of 28 item scores with the total score ranging from 0 (best) to 84 (worst). Under item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items are not included in the calculation of the total score. Item 11 or item 12 should be completed but not both, and similarly, item 13 or item 14 should be completed but not both. A negative change from baseline indicated improvement. LS mean was calculated using a MMRM analysis.
Time frame: Baseline to Week 8
Participants took part in this study at 15 investigative sites in Canada from 01 April 2021 to 27 May 2022.
| Milestone | Brexpiprazole |
|---|---|
| Started | 122 |
| Efficacy analysis set | 120 |
| Safety analysis set | 120 |
| Completed | 111 |
| Not completed | 11 |
| Withdrew: Adverse event | 6 |
| Withdrew: Failure to meet continuation criteria | 1 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Protocol deviation | 1 |
The IDS-SR-10 engagement consist of selected 10 item scores, including the following 10 items (clinician-selected): item 8 - Response of your mood to good or desired events, item 15 - Concentration/decision making, item 16 - View of myself, item 17 - View of my future, item 19 - General interest, item 20 - Energy level, item 21 - Capacity for pleasure or enjoyment (excluding sex), item 22 - Interest in sex (interest rated, not activity), item 23 - Feeling slowed down, and item 29- Interpersonal sensitivity. All the 10 items are rated on a 0 (best) to 3 (worst) scale. IDS-SR-10 engagement total score ranges from 0 (best) to 30 (worst). A negative change from baseline indicated improvement. Least square (LS) mean was calculated using a mixed model repeated measure (MMRM) analysis.
| score on a scale | Brexpiprazole |
|---|---|
| Change From Baseline in IDS-SR-10 Engagement | -8.11 ± 0.62 |
The IDS-SR is a 30-item self-report measure that was used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of major depressive disorder (MDD). Each item on the IDS-SR scale was rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. IDS-SR total score is the sum of ratings of 28 item scores with the total score ranging from 0 (best) to 84 (worst). Under item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items are not included in the calculation of the total score. Item 11 or item 12 should be completed but not both, and similarly, item 13 or item 14 should be completed but not both. A negative change from baseline indicated improvement. LS mean was calculated using a MMRM analysis.
| score on a scale | Brexpiprazole |
|---|---|
| Change From Baseline in IDS-SR Total Score | -17.38 ± 1.36 |
Collected over From first dose of study drug up to Week 8. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole | 0/120 (0%) | 0/120 (0%) | 45/120 (37.5%) |
| Event | Brexpiprazole |
|---|---|
| FatigueGeneral disorders | 13/120 |
| HeadacheNervous system disorders | 13/120 |
| InsomniaPsychiatric disorders | 12/120 |
| NauseaGastrointestinal disorders | 9/120 |
| TremorNervous system disorders | 8/120 |
| Weight increasedInvestigations | 7/120 |
The Enrolled Analysis Set included all participants who had signed the informed consent form (ICF) for the trial and had enrolled into the open-label treatment phase.
| Age, Continuous(years) | Brexpiprazole |
|---|---|
| Mean | 43.0 ± 13.1 |
| Sex: Female, Male(Participants) | Brexpiprazole |
|---|---|
| Female | 79 |
| Male | 43 |
| Race/Ethnicity, Customized(Participants) | Brexpiprazole |
|---|---|
| Race — White | 111 |
| Race — Black or African American | 1 |
| Race — Asian | 7 |
| Race — Other | 3 |
| Race/Ethnicity, Customized(Participants) | Brexpiprazole |
|---|---|
| Ethnicity — Hispanic or Latino | 1 |
| Ethnicity — Not Hispanic or Latino | 117 |
| Ethnicity — Unknown | 3 |
| Ethnicity — Other | 1 |
| IDS-SR-10 Engagement(score on a scale) | Brexpiprazole |
|---|---|
| Mean | 16.1 ± 4.7 |
| IDS-SR Total Score(score on a scale) | Brexpiprazole |
|---|---|
| Mean | 41.3 ± 9.8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Apr 2021 to primary completion in May 2022, 13 months.
Results were first posted in Feb 2024, 1 year 8 months after primary completion.
Of 98 phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →